Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.43 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14115540 | 0.94 | FOLH1 (0.46) | FOLH1SLC5A2USP2L3MBTL1CA9 | |
| SCHEMBL14415021 | 0.92 | CA9 (0.47) | SLC5A2USP2L3MBTL1CA9ALB | |
| SCHEMBL13024588 | 0.91 | P2RY6 (0.54) | FOLH1SLC5A2USP2L3MBTL1CA9 | |
| SCHEMBL10293949 | 0.91 | FOLH1 (0.46) | FOLH1SLC5A2USP2L3MBTL1CA9 | |
| SCHEMBL14415018 | 0.88 | ESR1 (0.47) | SLC5A2USP2L3MBTL1CA9ALB | |
| SCHEMBL14115544 | 0.86 | CA9 (0.46) | FOLH1SLC5A2USP2L3MBTL1CA9 | |
| SCHEMBL14415030 | 0.86 | ESR1 (0.47) | SLC5A2USP2L3MBTL1CA9HAVCR2 | |
| SCHEMBL14597203 | 0.85 | SLC5A2 (0.45) | FOLH1SLC5A2USP2L3MBTL1CA9 | |
| SCHEMBL14414996 | 0.85 | SLC5A2 (0.41) | FOLH1SLC5A2CA9P2RY6HAVCR2 | |
| SCHEMBL14415009 | 0.84 | ESR1 (0.54) | FOLH1SLC5A2USP2L3MBTL1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070212709-A1 | Non-nucleosidic linker linking xanthene donor to 4,7-dichlororhodamine acceptor; | APPLERA CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070212709-A1 | Non-nucleosidic linker linking xanthene donor to 4,7-dichlororhodamine acceptor; | DCLRE1A, SLC25A21, DIMT1 | FOLH1 3447/4885SLC5A2 3732/4885USP2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.